Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Fineline Cube Aug 31, 2026
Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Fineline Cube Aug 31, 2026
Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Fineline Cube Sep 1, 2026
Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Fineline Cube Sep 1, 2026
Company Drug

AstraZeneca’s Tezspire Meets Phase III Co-Primary Endpoints in CRSwNP Study

Fineline Cube Nov 11, 2024

AstraZeneca Inc., (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced positive high-level results...

Company Medical Device

Sino Medical Sciences Technology Secures Marketing Approval in Peru for HT Supreme Stent System

Fineline Cube Nov 11, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108), a leading Chinese medical technology company, has announced...

Company Drug

Jiangsu Kanion Pharmaceutical Gets FDA Approval to Test KYS202004A for Psoriasis

Fineline Cube Nov 11, 2024

Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a Chinese pharmaceutical company, has announced that it...

Company Drug

J&J Submits Regulatory Filings for Darzalex Faspro and Subcutaneous Daratumumab

Fineline Cube Nov 11, 2024

Johnson & Johnson (J&J, NYSE: JNJ) has announced the submission of regulatory filings for its...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Clearance for Multiple Clinical Trials of Oncology Drugs

Fineline Cube Nov 11, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a Chinese pharmaceutical company, has announced that it...

Company Drug

Alphamab Oncology Presents JSKN033 Phase I/II Study Results at SITC 2024

Fineline Cube Nov 11, 2024

Alphamab Oncology (HKG: 9966), a China-based biopharmaceutical company, has announced the presentation of the latest...

Company Drug

Sino Biopharmaceutical Ltd Receives NMPA Approval for KRAS G12C Inhibitor Garsorasib

Fineline Cube Nov 11, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company in China, has announced that it...

Company Deals Drug

Daiichi Sankyo and Alteogen Sign $300 Million Deal to Develop Subcutaneous Enhertu

Fineline Cube Nov 9, 2024

Daiichi Sankyo (TYO: 4568), a leading Japanese pharmaceutical company, has entered into a potentially $300...

Company Drug

Dizal Pharmaceutical Submits NDA to FDA for Sunvozertinib as NSCLC Therapy

Fineline Cube Nov 9, 2024

Dizal Pharmaceutical Co., Ltd (SHA: 688192), a Chinese pharmaceutical company, has announced the submission of...

Company Deals

MGI Tech Co., Ltd Partners with Human Cell Atlas Consortium to Advance Cell Mapping

Fineline Cube Nov 8, 2024

China-based gene sequencing specialist, MGI Tech Co., Ltd, (SHA: 688114) has announced a commercial collaboration...

Company

AstraZeneca Confirms Executive Vice President Leon Wang’s Detention in China

Fineline Cube Nov 8, 2024

AstraZeneca Inc., (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has provided an update to...

Company Deals

Jiangsu Kanion Pharmaceutical to Acquire Xintrum Pharmaceuticals for RMB 270 Million

Fineline Cube Nov 8, 2024

Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a China-based pharmaceutical company, has announced its intention...

Company Drug

Ascletis Pharma’s ASC47 Showcases Promising Weight Loss Results in Phase I Clinical Trial

Fineline Cube Nov 8, 2024

Ascletis Pharma Inc. (HKG: 1672), a China-based pharmaceutical company, has announced positive results from a...

Company Deals

Nuwacell Biotechnologies Secures RMB150 Million in Series B Financing for iPSC Therapies

Fineline Cube Nov 8, 2024

Nuwacell Biotechnologies Co., Ltd., a specialist in induced pluripotent stem cell (iPSC) technology based in...

Company Deals

Shanghai Henlius Biotech Partners with SVAX to Boost MENAT Region’s Access to Biological Drugs

Fineline Cube Nov 8, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a leading Chinese biotech company, has entered into a...

Company Medical Device

Johnson & Johnson MedTech’s Varipulse Platform Receives FDA Approval for Atrial Fibrillation Treatment

Fineline Cube Nov 8, 2024

Johnson & Johnson MedTech (J&J, NYSE: JNJ) has announced that it has received marketing approval...

Company Drug

Sichuan Biokin Pharmaceutical Gets FDA Approval for Phase I Study of BL-M17D1 in Solid Tumors

Fineline Cube Nov 8, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...

Company Medical Device

Bayer AG Receives FDA 510(k) Clearance for MEDRAD Centargo CT Injection System

Fineline Cube Nov 8, 2024

Germany-based Bayer AG (ETR: BAYN) has announced that it has received 510(k) clearance from the...

Company Drug

Sichuan Huiyu Pharmaceutical’s HYP-6589 Receives NMPA Approval for Solid Tumor Clinical Trial

Fineline Cube Nov 8, 2024

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...

Company Drug

Ascentage Pharma’s Lisaftoclax and AceLink Therapeutics’ AL01211 Receive FDA Designations

Fineline Cube Nov 8, 2024

The Center for Drug Evaluation (CDE) website has indicated that China-based Ascentage Pharma’s (HKG: 6855)...

Posts pagination

1 … 318 319 320 … 714

Recent updates

  • NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment
  • Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment
  • Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States
  • Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market
  • Laekna Doses First Patient in Phase I Study of LAE118 PI3Kα Inhibitor for Advanced Solid Tumors, Licensed to Vasque Bio for Up to USD 527 Million
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Company Drug

Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States

Policy / Regulatory

Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.